The Effects of the Nude (nu/nu) Mutation on Bleomycin-induced Pulmonary Fibrosis: A Biochemical Evaluation 1– 3
The DOI matches its Crossref record.
Abstract
Previous reports have suggested that the immune system is involved in the lung fibrogenic response to certain agents or treatments. In the present study, we have evaluated the impact of the athymic (nude) mutation on the development of pulmonary fibrosis in mice induced by a single intratracheal instillation of bleomycin (0.75 units/animal). Histologic examination revealed that cellular infiltration, fibroblast proliferation, and connective tissue accumulation were diminished in the nude mice when compared with euthymic (het) control mice. In contrast to control animals treated with saline, total lung hydroxyproline in the nude mouse was not significantly increased at 14 and 30 days after bleomycin treatment. Net collagen synthesis, as assessed by measuring the rate of incorporation of tritiated proline in an organ culture system, was increased above control values in both nude and euthymic mice at 14 days after bleomycin treatment, although these values returned to normal at 30 days. However, lung collagen synthetic rates, normalized to dry lung weights, were significantly higher at 14 days in euthymic bleomycin-treated control mice than in the nude bleomycin-treated animals. The data indicate that the nude athymic mutation protects, at least partially, against bleomycin-induced pulmonary fibrosis, thus suggesting a role for the cellular immune system in regulating the fibrogenic response to this drug.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Fibrogenic cytokines: the role of immune mediators in the development of scar tissue
Kovacs, E. J. (1991) · Immunology Today · doi:10.1016/0167-5699(91)90107-5 · Cited by 590
Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis.
Piguet, P. F., Collart, M. A., Grau, G. E., Kapanci, Y., & Vassalli, P. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.3.655 · Cited by 583
Eitzman, D. T., McCoy, R. D., Zheng, X., Fay, W. P., Shen, T., Ginsburg, D., & Simon, R. H. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118396 · Cited by 558
Inflammation and immunity in IPF pathogenesis and treatment
Heukels, P., Moor, C. C., von der Thüsen, J. H., Wijsenbeek, M. S., & Kool, M. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2018.12.015 · Cited by 517
Time course of bleomycin‐induced lung fibrosis
Izbicki, G., Segel, M. J., Christensen, T. G., Conner, M. W., & Breuer, R. (2002) · International Journal of Experimental Pathology · doi:10.1046/j.1365-2613.2002.00220.x · Cited by 447
Gharaee-Kermani, M., Denholm, E. M., & Phan, S. H. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.30.17779 · Cited by 435
Self-citationMolecular and cellular mechanisms of pulmonary fibrosis
Todd, N. W., Luzina, I. G., & Atamas, S. P. (2012) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-5-11 · Cited by 418
Drug-induced pulmonary disease
Cooper, J. A. D., & Matthay, R. A. (1987) · Disease-a-Month · doi:10.1016/0011-5029(87)90021-6 · Cited by 297
Savin, I. A., Zenkova, M. A., & Sen’kova, A. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314959 · Cited by 279
Apoptosis and expression of Fas/Fas ligand mRNA in bleomycin-induced pulmonary fibrosis in mice.
Hagimoto, N., Kuwano, K., Nomoto, Y., Kunitake, R., & Hara, N. (1997) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.16.1.8998084 · Cited by 274
The pathogenesis of idiopathic pulmonary fibrosis
Coward, W. R., Saini, G., & Jenkins, G. (2010) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465810379801 · Cited by 272
Avraham, T., Zampell, J. C., Yan, A., Elhadad, S., Weitman, E. S., Rockson, S. G., Bromberg, J., & Mehrara, B. J. (2013) · The FASEB Journal · doi:10.1096/fj.12-222695 · Cited by 241
Piguet, P. F., Vesin, C., Grau, G. E., & Thompson, R. C. (1993) · Cytokine · doi:10.1016/1043-4666(93)90024-y · Cited by 215
Roles of T lymphocytes in pulmonary fibrosis
Luzina, I. G., Todd, N. W., Iacono, A. T., & Atamas, S. P. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.0707504 · Cited by 163
(1986) · PubMed Central · Cited by 64
Overexpression of the transcription factor GATA-3 enhances the development of pulmonary fibrosis
Kimura, T., Ishii, Y., Yoh, K., Morishima, Y., Iizuka, T., Kiwamoto, T., Matsuno, Y., Homma, S., Nomura, A., Sakamoto, T., et al. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.051160 · Cited by 55
“Bleomycin-induced pulmonary inflammation and fibrosis were not observed in athymic nude mice.(8) These findings suggest that T cells participate in the pathophysiology of fibrosis in the bleomycin model.”
BackgroundRepetitive intradermal bleomycin injections evoke T-helper cell 2 cytokine-driven pulmonary fibrosis
Singh, B., Kasam, R. K., Sontake, V., Wynn, T. A., & Madala, S. K. (2017) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00184.2017 · Cited by 48
“have been shown to contribute to the pathogenesis of pulmonary fibrosis (1, 35).”
Background
Metadata
- Authors
- Schrier, D. J., Phan, S. H., & McGarry, B. M.
- Venue
- American Review of Respiratory Disease
- Publisher
- Oxford University Press (OUP)
- Published
- 1983-05
- Volume
- 127
- Issue
- 5
- Pages
- 614-617
- ISSN
- 0003-0805 (ISSN-L)
- OpenAlex
- W1604292228
- Cited by
- 148
- References
- 0
- FWCI
- 8.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.